A detailed history of Prelude Capital Management, LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 30,410 shares of BCAB stock, worth $41,053. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,410
Previous 30,410 -0.0%
Holding current value
$41,053
Previous $53,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.17 - $2.05 $35,579 - $62,340
30,410 New
30,410 $53,000
Q3 2023

Nov 14, 2023

SELL
$1.7 - $3.07 $8,358 - $15,095
-4,917 Reduced 30.73%
11,083 $18,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $8,925 - $12,205
3,154 Added 24.55%
16,000 $48,000
Q1 2023

May 15, 2023

SELL
$2.3 - $8.25 $7,652 - $27,447
-3,327 Reduced 20.57%
12,846 $34,000
Q4 2022

Feb 14, 2023

BUY
$6.29 - $11.01 $101,728 - $178,064
16,173 New
16,173 $133,000
Q2 2022

Aug 15, 2022

BUY
$2.13 - $5.38 $33,696 - $85,111
15,820 New
15,820 $45,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.